Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress
首发时间:2011-01-03
Abstract:Context: Ligustrazine (Lig) is a compound isolated from the rhizome of Ligusticum walliichi (Ligusticum Chuanxiong Hort) and has been reported to be effective for the treatment of a variety of vascular diseases.Objective: The anti-atherosclerotic activities of Lig are evaluated in vivo for the first time in the present study. Materials and methods: We gave rats a single injection of vitamin D3 and then fed them with an atherogenic diet for 6 weeks to induce atherosclerosis. Lig was simultaneously given to rats by gavage in the therapy groups. The effects of Lig on blood parameters, aorta and liver histology, and gene expression were investigated. In addition, the solely effects of Lig on food intake, body weight gain, and taste preference were also evaluated.Results: We found that Lig decreased the total cholesterol, triglyceride, and low density lipoprotein levels while it increased high density lipoprotein level in the plasma. The circulating endothelial cells were also decreased in Lig-treated rats, indicating the attenuation of endothelial injury. In contrast, Lig restored the total antioxidant capacity and SOD1 activity while decreasing the MDA generation. Furthermore, Lig improved liver dysfunction by decreasing ALT and AST levels. Histological examinations revealed that Lig suppressed atherosclerotic plaque progression in the thoracic aorta and lipid accumulation in the liver. At the transcriptional level, Lig inhibited the induction of antioxidant genes both in aorta and in liver. Lig also suppressed the mRNA expression of the genes involved in the hepatic fatty acid oxidation. Finally, Lig had a minimum effect on food intake, body weight gain, and taste preference.Discussion and conclusion: Our results suggest that Lig suppresses the development of atherosclerosis and hepatic lipid accumulation via the alleviation of oxidative stress and the improvement of dyslipidemia.
keywords: Ligustrazine atherosclerosis oxidative stress dyslipidemia
点击查看论文中文信息
川芎嗪通过减少氧化压力缓解大鼠动脉粥样硬化症状的研究
摘要:背景:川芎嗪是从川芎根茎分离出的一种化合物,据报道对多种心血管疾病的治疗是有效的。目的:首次研究川芎嗪在体内的抗动脉粥样硬化效果。材料和方法:大鼠单次注射维生素D3,然后6周高脂饮食诱发动脉粥样硬化。治疗组的大鼠同时用川芎嗪灌胃。对大鼠血液相关指标,主动脉和肝脏组织学以及基因表达进行了研究。此外,对大鼠食物的摄入量,体重和味觉偏好进行了评价。结果:川芎嗪降低了大鼠血浆中总胆固醇,甘油三酯和低密度脂蛋白的水平,同时增加了高密度脂蛋白水平。川芎嗪也减少了血浆中的循环内皮细胞数。与此相反,川芎嗪恢复了总抗氧化能力和SOD1的水平,同时降低了丙二醛的产生。此外,川芎嗪通过降低ALT和AST水平改善肝脏损伤。组织学检测发现,川芎嗪抑制动脉粥样硬化斑块在胸主动脉上的形成以及肝脏中脂肪的积聚。在基因转录水平,川芎嗪抑制抗氧化基因在主动脉和肝脏的表达,同时川芎嗪抑制肝脏与脂肪酸氧化相关基因的表达。最后,川芎嗪对大鼠摄食量,体重变化和味觉偏好无明显影响。结论:我们的研究结果表明,川芎嗪通过缓解氧化压力和改善血脂异常,抑制大鼠动脉粥样硬化的发展和减轻肝脏的脂质堆积。
论文图表:
引用
No.4401385556856129****
同行评议
共计0人参与
勘误表
川芎嗪通过减少氧化压力缓解大鼠动脉粥样硬化症状的研究
评论
全部评论0/1000